From Wikipedia, the free encyclopedia
  (Redirected from LY-334,370)
Jump to: navigation, search
IUPAC name
Other names
182563-08-2 YesY
ChemSpider 4470773 N
IUPHAR ligand 20
Jmol-3D images Image
MeSH C108218
PubChem 5311258
Molar mass 351.42 g/mol
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N verify (what isYesY/N?)
Infobox references

LY-334370 is a selective 5-HT1F receptor agonist[1] which was under development by Eli Lilly and Company for the treatment of migraine headaches.[2] The drug showed efficacy in a phase II clinical trial[3] but further development was halted due to toxicity detected in animals.[4]

See also[edit]


  1. ^ Dupuis DS, Colpaert FC, Pauwels PJ (1998). "G-protein activation at 5-HT1A receptors by the 5-HT1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines". Br. J. Pharmacol. 124 (2): 283–90. doi:10.1038/sj.bjp.0701832. PMC 1565387. PMID 9641544. 
  2. ^ Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). "Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY-334,370". Cephalalgia 19 (10): 851–8. doi:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103. 
  3. ^ Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). "Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial". Lancet 358 (9289): 1230–4. doi:10.1016/S0140-6736(01)06347-4. PMID 11675061. 
  4. ^ Ramadan NM, Buchanan TM (2006). "New and future migraine therapy". Pharmacol. Ther. 112 (1): 199–212. doi:10.1016/j.pharmthera.2005.04.010. PMID 16797716. 

External links[edit]